{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:57:15Z","timestamp":1790693835531,"version":"4.1.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2027,3]]},"DOI":"10.1016\/j.vhri.2026.102144","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:01:49Z","timestamp":1790690509000},"page":"102144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Making Structural Uncertainty Transparent in Locally Informed Health Economic Models on HIV Treatment"],"prefix":"10.1016","volume":"58","author":[{"given":"Quang D.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton L.V.","family":"Avance\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.vhri.2026.102144_bib2","doi-asserted-by":"crossref","first-page":"e1648","DOI":"10.1016\/S2214-109X(23)00383-2","article-title":"Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis","volume":"11","author":"Phillips","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"2","key":"10.1016\/j.vhri.2026.102144_bib3","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/S2352-3018(18)30317-5","article-title":"Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study","volume":"6","author":"Phillips","year":"2019","journal-title":"Lancet HIV"},{"issue":"3","key":"10.1016\/j.vhri.2026.102144_bib4","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S2352-3018(17)30190-X","article-title":"Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study","volume":"5","author":"Phillips","year":"2018","journal-title":"Lancet HIV"},{"issue":"0","key":"10.1016\/j.vhri.2026.102144_bib5","article-title":"Cost-utility analysis of dolutegravir versus efavirenz-based regimens for HIV treatment in Indonesia: a model-based extrapolation from primary healthcare settings","volume":"0","author":"Zakiyah","year":"2026","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"10.1016\/j.vhri.2026.102144_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12962-019-0195-2","article-title":"Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients","volume":"17","author":"Punekar","year":"2019","journal-title":"Cost Eff Resour Alloc"},{"issue":"3","key":"10.1016\/j.vhri.2026.102144_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25085","article-title":"The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India","volume":"21","author":"Zheng","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.vhri.2026.102144_bib8","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.vhri.2020.11.010","article-title":"Cost-effectiveness of Juluca for human immunodeficiency virus infection treatment in Virologically suppressed adults in Taiwan","volume":"24","author":"Anderson","year":"2021","journal-title":"Value Health Reg Issues"},{"issue":"5","key":"10.1016\/j.vhri.2026.102144_bib9","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working Group\u20136","volume":"32","author":"Briggs","year":"2012","journal-title":"Med Decis Mak"},{"issue":"6","key":"10.1016\/j.vhri.2026.102144_bib10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","article-title":"Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task Force \u2014 6","volume":"15","author":"Briggs","year":"2012","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.vhri.2026.102144_bib11","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jval.2012.06.011","article-title":"Dynamic transmission modeling: a report of the ISPOR-SMDM modeling good research practices task Force\u20145","volume":"15","author":"Pitman","year":"2012","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.vhri.2026.102144_bib12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","article-title":"Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task Force--7","volume":"15","author":"Eddy","year":"2012","journal-title":"Value Health"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926005595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926005595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:01:51Z","timestamp":1790690511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109926005595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,3]]},"references-count":11,"alternative-id":["S2212109926005595"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.102144","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2027,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Making Structural Uncertainty Transparent in Locally Informed Health Economic Models on HIV Treatment","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.102144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"102144"}}